Jan 10 (Reuters) - NYXOAH SA NYXH.BR :
* NYXOAH PROVIDES GENERAL CORPORATE UPDATE
* IMPLANTED FIRST U.S. PATIENT IN DREAM IDE PIVOTAL STUDY IN
DECEMBER 2020; THERE ARE CURRENTLY 15 ACTIVE AND ENROLLING
PATIENT SITES IN U.S., WITH IMPLANTS EXPECTED TO BE COMPLETED IN
Q1 2022
* SPRINT DISCUSSIONS WITH FDA REGARDING IDE STUDY FOR CCC
PATIENTS
IN U.S., WHICH NYXOAH HOPES TO COMMENCE IN SECOND HALF OF 2022
* AS PROUD AND EXCITED AS WE ARE OF OUR SIGNIFICANT
ACCOMPLISHMENTS IN 2021, WE HAVE OUR SIGHTS SET MUCH HIGHER FOR
2022 - TAELMAN
Source text for Eikon: ID:nGNX89bNqp
Further company coverage: NYXH.BR
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 587 696 600;))